Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

The Higher the Grade, the Bigger the Field.

Beckta JM, Bindra RS.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):488-489. doi: 10.1016/j.ijrobp.2018.08.019. No abstract available.

PMID:
30238899
2.

Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.

Sulkowski PL, Sundaram RK, Oeck S, Corso CD, Liu Y, Noorbakhsh S, Niger M, Boeke M, Ueno D, Kalathil AN, Bao X, Li J, Shuch B, Bindra RS, Glazer PM.

Nat Genet. 2018 Aug;50(8):1086-1092. doi: 10.1038/s41588-018-0170-4. Epub 2018 Jul 16.

PMID:
30013182
3.

Biodegradable PEG-poly(ω-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors.

Chen EM, Quijano AR, Seo YE, Jackson C, Josowitz AD, Noorbakhsh S, Merlettini A, Sundaram RK, Focarete ML, Jiang Z, Bindra RS, Saltzman WM.

Biomaterials. 2018 Sep;178:193-203. doi: 10.1016/j.biomaterials.2018.06.024. Epub 2018 Jun 18.

PMID:
29936153
4.

CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma.

Chen WS, Bindra RS, Mo A, Hayman T, Husain Z, Contessa JN, Gaffney SG, Townsend JP, Yu JB.

Front Oncol. 2018 Apr 4;8:95. doi: 10.3389/fonc.2018.00095. eCollection 2018.

5.

Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.

Marks AM, Bindra RS, DiLuna ML, Huttner A, Jairam V, Kahle KT, Kieran MW.

Pediatr Blood Cancer. 2018 May;65(5):e26969. doi: 10.1002/pbc.26969. Epub 2018 Jan 30.

PMID:
29380516
6.

Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes.

Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB.

Lancet Oncol. 2018 Jan;19(1):23-24. doi: 10.1016/S1470-2045(17)30916-6. No abstract available.

PMID:
29304353
7.

Introduction to the Yale Precision Medicine Tumor Board.

Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB.

Lancet Oncol. 2018 Jan;19(1):19-20. doi: 10.1016/S1470-2045(17)30919-1. No abstract available.

PMID:
29304351
8.

Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging.

Chang K, Bai HX, Zhou H, Su C, Bi WL, Agbodza E, Kavouridis VK, Senders JT, Boaro A, Beers A, Zhang B, Capellini A, Liao W, Shen Q, Li X, Xiao B, Cryan J, Ramkissoon S, Ramkissoon L, Ligon K, Wen PY, Bindra RS, Woo J, Arnaout O, Gerstner ER, Zhang PJ, Rosen BR, Yang L, Huang RY, Kalpathy-Cramer J.

Clin Cancer Res. 2018 Mar 1;24(5):1073-1081. doi: 10.1158/1078-0432.CCR-17-2236. Epub 2017 Nov 22.

PMID:
29167275
9.

Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery.

Chowdhary M, Okwan-Duodu D, Switchenko JM, Press RH, Jhaveri J, Buchwald ZS, Zhong J, Chapman BV, Bindra RS, Contessa JN, Park HS, Yu JB, Decker RH, Olson JJ, Oyesiku NM, Abrams RA, Shu HG, Curran WJ Jr, Crocker IR, Patel KR.

J Neurooncol. 2018 Jan;136(2):289-298. doi: 10.1007/s11060-017-2652-0. Epub 2017 Nov 9.

10.

Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas.

Yeboa DN, Rutter CE, Park HS, Lester-Coll NH, Corso CD, Mancini BR, Bindra RS, Contessa J, Yu JB.

Radiother Oncol. 2017 Nov;125(2):258-265. doi: 10.1016/j.radonc.2017.09.027. Epub 2017 Oct 17.

PMID:
29054377
11.

State of the art: the evolving role of RT in combined modality therapy for GBM.

Bindra RS, Galanis E, Mehta MP.

J Neurooncol. 2017 Sep;134(3):477-478. doi: 10.1007/s11060-017-2596-4. No abstract available.

12.

SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination.

Daddacha W, Koyen AE, Bastien AJ, Head PE, Dhere VR, Nabeta GN, Connolly EC, Werner E, Madden MZ, Daly MB, Minten EV, Whelan DR, Schlafstein AJ, Zhang H, Anand R, Doronio C, Withers AE, Shepard C, Sundaram RK, Deng X, Dynan WS, Wang Y, Bindra RS, Cejka P, Rothenberg E, Doetsch PW, Kim B, Yu DS.

Cell Rep. 2017 Aug 22;20(8):1921-1935. doi: 10.1016/j.celrep.2017.08.008.

13.

GBM radiosensitizers: dead in the water…or just the beginning?

Bindra RS, Chalmers AJ, Evans S, Dewhirst M.

J Neurooncol. 2017 Sep;134(3):513-521. doi: 10.1007/s11060-017-2427-7. Epub 2017 Jul 31. Review.

PMID:
28762004
14.

Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas.

King AR, Corso CD, Chen EM, Song E, Bongiorni P, Chen Z, Sundaram RK, Bindra RS, Saltzman WM.

Mol Cancer Ther. 2017 Aug;16(8):1456-1469. doi: 10.1158/1535-7163.MCT-16-0788. Epub 2017 May 31.

15.

The role of radiation in treating glioblastoma: here to stay.

Corso CD, Bindra RS, Mehta MP.

J Neurooncol. 2017 Sep;134(3):479-485. doi: 10.1007/s11060-016-2348-x. Epub 2017 Mar 7. Review.

PMID:
28271281
16.

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.

Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur K, De Feyter HM, de Graaf RA, Surovtseva YV, Kachman M, Halene S, Günel M, Glazer PM, Bindra RS.

Sci Transl Med. 2017 Feb 1;9(375). pii: eaal2463. doi: 10.1126/scitranslmed.aal2463.

17.

The impact of cobalt-60 source age on biologically effective dose in high-dose functional Gamma Knife radiosurgery.

Kann BH, Yu JB, Stahl JM, Bond JE, Loiselle C, Chiang VL, Bindra RS, Gerrard JL, Carlson DJ.

J Neurosurg. 2016 Dec;125(Suppl 1):154-159.

PMID:
27903196
18.

Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions.

Corso CD, Bindra RS.

Semin Radiat Oncol. 2016 Oct;26(4):281-98. doi: 10.1016/j.semradonc.2016.06.003. Epub 2016 Jun 3. Review.

PMID:
27619250
19.

Adjuvant chemotherapy and overall survival in adult medulloblastoma.

Kann BH, Lester-Coll NH, Park HS, Yeboa DN, Kelly JR, Baehring JM, Becker KP, Yu JB, Bindra RS, Roberts KB.

Neuro Oncol. 2017 Feb 1;19(2):259-269. doi: 10.1093/neuonc/now150.

20.

Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children.

Kann BH, Park HS, Lester-Coll NH, Yeboa DN, Benitez V, Khan AJ, Bindra RS, Marks AM, Roberts KB.

JAMA Oncol. 2016 Dec 1;2(12):1574-1581. doi: 10.1001/jamaoncol.2016.2547. Erratum in: JAMA Oncol. 2016 Dec 1;2(12 ):1661.

PMID:
27491009
21.

A single double-strand break system reveals repair dynamics and mechanisms in heterochromatin and euchromatin.

Janssen A, Breuer GA, Brinkman EK, van der Meulen AI, Borden SV, van Steensel B, Bindra RS, LaRocque JR, Karpen GH.

Genes Dev. 2016 Jul 15;30(14):1645-57. doi: 10.1101/gad.283028.116.

22.

Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay.

Surovtseva YV, Jairam V, Salem AF, Sundaram RK, Bindra RS, Herzon SB.

J Am Chem Soc. 2016 Mar 23;138(11):3844-55. doi: 10.1021/jacs.6b00162. Epub 2016 Mar 9.

23.

Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery.

Rutter CE, Johung KL, Yao X, Lu AY, Jilaveanu LB, Yu JB, Contessa JN, Kluger HM, Chiang VLS, Bindra RS.

J Radiosurg SBRT. 2016;4(2):97-106.

24.

A contemporary dose selection algorithm for stereotactic radiosurgery in the treatment of brain metastases - An initial report.

Colaco RJ, Yu JB, Bond JS, Bindra RS, Contessa JN, Knisely JPS, Chiang VL.

J Radiosurg SBRT. 2016;4(1):43-52.

25.

Adjuvant hypofractionated partial-brain radiation therapy for pediatric Ewing sarcoma brain metastases: case report.

van Dams R, Park HS, Alomari AK, Ricciardi AS, Rao H, McNamara J, DiLuna ML, Bindra RS.

J Neurosurg Pediatr. 2016 Apr;17(4):434-8. doi: 10.3171/2015.8.PEDS15313. Epub 2015 Dec 4.

PMID:
26636250
26.

Advances in Radiation Therapy in Pediatric Neuro-oncology.

Bindra RS, Wolden SL.

J Child Neurol. 2016 Mar;31(4):506-16. doi: 10.1177/0883073815597758. Epub 2015 Aug 13. Review.

PMID:
26271789
27.

Development of a novel method to create double-strand break repair fingerprints using next-generation sequencing.

Soong CP, Breuer GA, Hannon RA, Kim SD, Salem AF, Wang G, Yu R, Carriero NJ, Bjornson R, Sundaram RK, Bindra RS.

DNA Repair (Amst). 2015 Feb;26:44-53. doi: 10.1016/j.dnarep.2014.12.002. Epub 2014 Dec 19.

PMID:
25547252
28.

Identification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitors.

Goglia AG, Delsite R, Luz AN, Shahbazian D, Salem AF, Sundaram RK, Chiaravalli J, Hendrikx PJ, Wilshire JA, Jasin M, Kluger HM, Glickman JF, Powell SN, Bindra RS.

Mol Cancer Ther. 2015 Feb;14(2):326-42. doi: 10.1158/1535-7163.MCT-14-0765. Epub 2014 Dec 15.

29.

Delayed cerebral vasculopathy following cranial radiation therapy for pediatric tumors.

Wang C, Roberts KB, Bindra RS, Chiang VL, Yu JB.

Pediatr Neurol. 2014 Jun;50(6):549-56. doi: 10.1016/j.pediatrneurol.2013.09.018. Epub 2014 Jan 25. Review.

PMID:
24739378
30.

In regards to decision making for reirradiation of a recurrent intramedullary spinal cord metastasis.

Rutter CE, Yu JB, Carlson DJ, Husain ZA, Zhao S, Picone J, Bindra RS.

J Radiosurg SBRT. 2014;3(2):165-168. No abstract available.

31.

Radiation sensitivity and sensitization in melanoma.

Shahbazian D, Bindra RS, Kluger HM, Glazer PM.

Pigment Cell Melanoma Res. 2013 Nov;26(6):928-30. doi: 10.1111/pcmr.12147. Epub 2013 Aug 12. No abstract available.

32.

Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells.

Bindra RS, Goglia AG, Jasin M, Powell SN.

Nucleic Acids Res. 2013 Jun;41(11):e115. doi: 10.1093/nar/gkt255. Epub 2013 Apr 12.

33.

The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again.

Bindra RS, Yahalom J.

Expert Rev Anticancer Ther. 2011 Sep;11(9):1367-78. doi: 10.1586/era.11.88. Review.

PMID:
21929311
34.

Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.

Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2201-6. doi: 10.1073/pnas.0904783107. Epub 2010 Jan 19.

35.

Introduction: the evolving picture of the hypoxic tumour microenvironment.

Glazer PM, Bindra RS.

Curr Mol Med. 2009 May;9(4):399-400. No abstract available.

PMID:
19519396
36.

Targeting the DNA damage response for cancer therapy.

Powell SN, Bindra RS.

DNA Repair (Amst). 2009 Sep 2;8(9):1153-65. doi: 10.1016/j.dnarep.2009.04.011. Epub 2009 Jun 5. Review.

PMID:
19501553
37.

Regulation of DNA repair in hypoxic cancer cells.

Bindra RS, Crosby ME, Glazer PM.

Cancer Metastasis Rev. 2007 Jun;26(2):249-60. Review.

PMID:
17415527
38.

Co-repression of mismatch repair gene expression by hypoxia in cancer cells: role of the Myc/Max network.

Bindra RS, Glazer PM.

Cancer Lett. 2007 Jul 8;252(1):93-103. Epub 2007 Feb 1.

PMID:
17275176
39.

Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression.

Huang LE, Bindra RS, Glazer PM, Harris AL.

J Mol Med (Berl). 2007 Feb;85(2):139-48. Epub 2006 Dec 20. Review.

PMID:
17180667
40.

Basal repression of BRCA1 by multiple E2Fs and pocket proteins at adjacent E2F sites.

Bindra RS, Glazer PM.

Cancer Biol Ther. 2006 Oct;5(10):1400-7. Epub 2006 Oct 30.

PMID:
17106239
41.

CHK2-dependent phosphorylation of BRCA1 in hypoxia.

Gibson SL, Bindra RS, Glazer PM.

Radiat Res. 2006 Oct;166(4):646-51.

PMID:
17007555
42.

Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia.

Bindra RS, Glazer PM.

Oncogene. 2007 Mar 29;26(14):2048-57. Epub 2006 Sep 25.

PMID:
17001309
43.

Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability.

Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM.

Ann N Y Acad Sci. 2005 Nov;1059:184-95.

PMID:
16382054
44.

Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.

Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK, Glazer PM.

Cancer Res. 2005 Dec 15;65(24):11597-604.

45.

Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner.

Gibson SL, Bindra RS, Glazer PM.

Cancer Res. 2005 Dec 1;65(23):10734-41.

46.

Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells.

Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, Bristow RG.

Radiother Oncol. 2005 Aug;76(2):168-76.

PMID:
16026872
47.
48.

Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells.

Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM.

Mol Cell Biol. 2004 Oct;24(19):8504-18.

49.

Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells.

Mihaylova VT, Bindra RS, Yuan J, Campisi D, Narayanan L, Jensen R, Giordano F, Johnson RS, Rockwell S, Glazer PM.

Mol Cell Biol. 2003 May;23(9):3265-73.

50.

VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.

Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD.

Cancer Res. 2002 Jun 1;62(11):3014-9.

Supplemental Content

Loading ...
Support Center